Methotrexate osteopathy, does it exist?

K Maenaut; R Westhovens; J Dequeker

Home/Archive/PubMed

PubMed · 8970056

Methotrexate osteopathy, does it exist?

K Maenaut·R Westhovens·J Dequeker

View original source ↗Export metadata ↓

Abstract

We describe 2 postmenopausal women with rheumatoid arthritis (RA). They developed fractures during their treatment with weekly low dose methotrexate (MTX). The adverse effect of longterm low dose regimens of MTX on bone metabolism has been described as "methotrexate osteopathy," an analogy of the syndrome known in pediatric oncology. MTX may be an additional risk factor for osteoporosis and fractures in RA. This therapy should be relatively contraindicated in patients with multiple risk factors for osteoporosis.

Explore related subjects

Antirheumatic Agents Arthritis, Rheumatoid Bone Diseases Dose-Response Relationship, Drug Female Fractures, Stress Humans Methotrexate Middle Aged Postmenopause Radiography Radionuclide Imaging Time Factors Case Reports Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

K Maenaut, R Westhovens, J Dequeker. 1996. Methotrexate osteopathy, does it exist?. https://pubmed.ncbi.nlm.nih.gov/8970056/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

Interleukin (IL)-1beta-mediated apoptosis of human astrocytes.

Apoptosis of brain cells is observed in many inflammatory disorders of the central nervous system. Nitric oxide (NO) has been shown to induce apoptosis in several brain cell types, but not previously in astrocytes. In the present study, the hypothesis was examined that interleukin (IL)-1beta would induce production of NO by astrocytes which, in turn, would signal apoptotic death in these glial cells. TUNEL staining demonstrated apoptosis in astrocytes treated with IL-1beta. Using an ELISA method, IL-1 receptor antagonist protein completely abrogated this astrocyte apoptosis, while N(G)monomethyl-L-arginine partially prevented apoptosis but almost entirely blocked NO production. Thus, IL-1beta appears to signal apoptosis of astrocytes by a mechanism involving, in part, the induction of NO.

Antirheumatic Agents↗

PubMed1999

Issues in rheumatoid arthritis.

Explore the source record for details and available documents.

Antirheumatic Agents↗

PubMed1999

[Methotrexate and folates in rheumatoid arthritis].

The efficacy of weekly low-dose methotrexate treatment of rheumatoid arthritis is well documented. Efficacy and adverse events are both dose dependent, and side effects rather than lack of response are the main reason for discontinuing therapy. Several adverse effects appear to be related to folate deficiencies, and are largely due to the antifolate properties of methotrexate. In order to diminish side effects without compromising drug efficacy, clinical trials have been performed using folic acid or folinic acid concomitantly with methotrexate. Important to this achievement are both the timing of folate supplementation and the weekly folate-to-methotrexate ratio. Considering these and other factors, an individually adjusted supply of folic acid is proposed. For several patients a properly balanced diet is sufficient; they do not need additional folate supplements when using methotrexate.

Antirheumatic Agents↗